Molecular Testing in Non-Small Cell Lung Cancer Webinar Series - Appropriate Selection of Therapy in NSCLC Using Biomarker Data
Testing appropriate patients with advanced non-small cell lung cancer (NSCLC) for ALK rearrangements and EGFR mutations is critically important to ensure delivery of the most effective lung cancer treatment. Crizotinib is effective in treating ALK rearranged tumors, and erlotinib is effective in tumors with activating mutations in EGFR, leading in recent years to dramatic responses in selected groups of patients treated with these drugs. The NCCN Clinical Practice Guidelines for NSCLC currently recommend ALK rearrangement testing and EGFR mutation testing for patients with advanced nonsquamous NSCLC. Using these tests to select targeted therapy has been shown to improve outcomes for the patients carrying one of these mutations. However, many patients with advanced nonsquamous NSCLC are not receiving molecular testing because of gaps in physician knowledge of its critical importance as well as lack of patient awareness.
The March 7th kickoff webinar in this series will introduce cases with the objective of describing the respective contributions made by various members of the multidisciplinary team in the management of NSCLC. Subsequent webinars will focus on the individual needs of each of the specialties involved in testing and providing specific guidance on how to ensure appropriate management.
Throughout this series, the goal is to ensure that pathologists, medical oncologists, radiation oncologists, surgical oncologists, interventional radiologists, pulmonologists, nurses, and other relevant healthcare professionals have the knowledge and skills necessary to order, perform, and use the information acquired from biomarker testing to optimally manage patients with advanced NSCLC.
This activity is designed to meet the educational needs of medical oncologists, radiation oncologists, surgical oncologists, pathologists, nurses, pharmacists, and other healthcare professionals who manage patients with non-small cell lung cancer.
Following this activity, participants should be able to:
- Describe the appropriate selection of therapies for patients with NSCLC using biomarker data
Gregory A. Otterson, MD (program chair)
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research
This activity is approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided. View complete accreditation information
- 1.00 Participation
- 1.00 Nurse
- 1.00 Pharmacist
- 1.00 Physician